RBC Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform, 'See Potential For Obicetrapib To Be a Best-In-Class CETP Inhibitor'

October 30, 2023 2:12 AM EDT Send to a Friend
(Updated - October 30, 2023 5:11 AM EDT)

RBC Capital analyst Leonid Timashev initiates coverage on NewAmsterdam Pharma Co ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login